Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma
Sponsor study identifier
interventional
182
1 country
12
Study Start
November 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2014
Actual (reported)Study Completion
June 2014
Actual (reported)The study was set up to assess the efficacy and tolerability of a chemotherapy-immunotherapy combination programme originally introduced by GMALL (the German cooperative group for adult acute lymphoblastic leukemia)in 2002, to improve remission rate, overall and disease-free survival rates of adult patients with Burkitt's leukemia and lymphoma. The therapy includes a maximum of six chemotherapy courses (two with high doses of methotrexate and cytarabine) plus anti-CD20 antibody (Rituximab, up to 8 total doses), supplemented by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2002
Date type not reportedThis date has not been verified as actual or estimated.
February 2, 2011
Actual (reported)February 4, 2011
Actual (reported)June 2014
Actual (reported)June 2014
Actual (reported)Overall survival
Percentage of patients alive without disease at 5 years from date of diagnosis
5 years
Disease free survival
5 years
Cumulative incidence of relapse
5 years
Complete remission rate
Up to 24 weeks
Toxicity
1 year
Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Divisione di Ematologia e TMO, Ospedale San Maurizio
Bolzano, (bz), Italy
Ematologia e centro TMO - Ospedale Armando Businco
Cagliari, (ca), Italy
S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle
Cuneo, (cn), Italy
Onco-Ematologia - Ospedale Civile
Noale, (ve), Italy
Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo
Alessandria, AL, Italy
USC Ematologia Ospedali Riuniti di Bergamo
Bergamo, BG, Italy
Divisione Ematologia Spedali Civili
Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gokbuget N, Bassan R. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013 Nov;98(11):1718-25. doi: 10.3324/haematol.2013.086827. Epub 2013 Jun 10.
Renato Bassan, MD
USC Ematologia Ospedali Riuniti di Bergamo
182 participants (actual enrollment reported by the registry).
First Submitted
February 2, 2011
First Posted
February 4, 2011
Study Start
November 2002
Date type not reportedThis date has not been verified as actual or estimated.
Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Contact the study team to confirm eligibility.
Brescia, BS, 25123, Italy
Ematologia - AOU Careggi
Florence, FI, Italy
Ematologia e TMO - Ospedale San Raffaele
Milan, MI, Italy
Ematologia - TMO - Ospedale San Gerardo
Monza, MI, Italy
Ematologia Ospedale San Bortolo
Vicenza, VI, 36100, Italy
USC Ematologia Ospedali Riuniti di Bergamo
Bergamo, 24128, Italy
Primary Completion
June 2014
Actual (reported)Study Completion
June 2014
Actual (reported)Last Updated
September 16, 2014
Record last verified: 2014-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: